Cardinal Health (CAH) increased its fiscal 2024 outlook for non-GAAP earnings per share by $0.05 to $6.50 to $6.75 from the preliminary outlook of $6.45 to $6.70, which primarily reflects increased expectations for Pharmaceutical segment profit. The company reiterated its fiscal 2024 Pharmaceutical segment profit outlook for 4% to 6% growth on higher ending fiscal 2023 Pharmaceutical segment profit. The company also increased its fiscal year 2024 Pharmaceutical revenue outlook, driven by continued growth of GLP-1 medications, which do not meaningfully contribute to segment profit.
Fourth-quarter GAAP operating earnings were $137 million, primarily due to a non-cash, pre-tax goodwill impairment charge of $368 million in the Medical segment. Net loss attributable to Cardinal Health was $64 million compared to profit of $138 million, previous year. GAAP loss per share was $0.25, compared to profit of $0.50. The GAAP loss was primarily due to the impairment, net of tax effects.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.